JP2022524741A - セリネクソールの共結晶形態 - Google Patents

セリネクソールの共結晶形態 Download PDF

Info

Publication number
JP2022524741A
JP2022524741A JP2021552142A JP2021552142A JP2022524741A JP 2022524741 A JP2022524741 A JP 2022524741A JP 2021552142 A JP2021552142 A JP 2021552142A JP 2021552142 A JP2021552142 A JP 2021552142A JP 2022524741 A JP2022524741 A JP 2022524741A
Authority
JP
Japan
Prior art keywords
serinexol
succinic acid
crystal
vanillin
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021552142A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524741A5 (https=
Inventor
ハミルトン、クリフトン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson Matthey PLC
Original Assignee
Johnson Matthey PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson Matthey PLC filed Critical Johnson Matthey PLC
Publication of JP2022524741A publication Critical patent/JP2022524741A/ja
Publication of JP2022524741A5 publication Critical patent/JP2022524741A5/ja
Priority to JP2025106508A priority Critical patent/JP2025134935A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C07C47/58—Vanillin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021552142A 2019-03-20 2020-03-19 セリネクソールの共結晶形態 Pending JP2022524741A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025106508A JP2025134935A (ja) 2019-03-20 2025-06-24 セリネクソールの共結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962821203P 2019-03-20 2019-03-20
US62/821,203 2019-03-20
PCT/US2020/023530 WO2020191140A1 (en) 2019-03-20 2020-03-19 Co-crystal forms of selinexor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025106508A Division JP2025134935A (ja) 2019-03-20 2025-06-24 セリネクソールの共結晶形態

Publications (2)

Publication Number Publication Date
JP2022524741A true JP2022524741A (ja) 2022-05-10
JP2022524741A5 JP2022524741A5 (https=) 2024-11-18

Family

ID=70293085

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021552142A Pending JP2022524741A (ja) 2019-03-20 2020-03-19 セリネクソールの共結晶形態
JP2025106508A Pending JP2025134935A (ja) 2019-03-20 2025-06-24 セリネクソールの共結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025106508A Pending JP2025134935A (ja) 2019-03-20 2025-06-24 セリネクソールの共結晶形態

Country Status (8)

Country Link
US (1) US12559478B2 (https=)
EP (1) EP3941588A1 (https=)
JP (2) JP2022524741A (https=)
KR (1) KR20210141936A (https=)
CN (1) CN113423468A (https=)
BR (1) BR112021016762A2 (https=)
CA (1) CA3130107A1 (https=)
WO (1) WO2020191140A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021016762A2 (pt) 2019-03-20 2021-10-19 Johnson Matthey Public Limited Company Cocristal de selinexor, composição farmacêutica, método de tratamento de doenças, e, processo para a preparação de cocristal de selinexor

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013512886A (ja) * 2009-12-03 2013-04-18 アストラゼネカ アクチボラグ 血小板の凝集阻害剤トリアゾロ［４，５−ｄ］ピリミジン共結晶
JP2014521652A (ja) * 2011-07-29 2014-08-28 カリオファーム セラピューティクス，インコーポレイテッド ヒドラジド含有核輸送調節因子およびその使用
CN107089946A (zh) * 2017-05-05 2017-08-25 浙江科技学院 一种诺氟沙星与香兰素共晶及其制备方法
US20180000808A1 (en) * 2013-03-26 2018-01-04 Celgene Corporation Solid forms comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
WO2018129227A1 (en) * 2017-01-05 2018-07-12 Watson Laboratories Inc. Novel crystalline forms of selinexor and process for their preparation
US20180230140A1 (en) * 2014-06-30 2018-08-16 Basf Se Multicomponent crystals of dasatinib with menthol or vanillin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102608259B1 (ko) 2014-08-15 2023-11-29 카리오팜 쎄라퓨틱스, 인코포레이티드 셀리넥소의 다형태
WO2017118940A1 (en) * 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
BR112021016762A2 (pt) 2019-03-20 2021-10-19 Johnson Matthey Public Limited Company Cocristal de selinexor, composição farmacêutica, método de tratamento de doenças, e, processo para a preparação de cocristal de selinexor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013512886A (ja) * 2009-12-03 2013-04-18 アストラゼネカ アクチボラグ 血小板の凝集阻害剤トリアゾロ［４，５−ｄ］ピリミジン共結晶
JP2014521652A (ja) * 2011-07-29 2014-08-28 カリオファーム セラピューティクス，インコーポレイテッド ヒドラジド含有核輸送調節因子およびその使用
US20180000808A1 (en) * 2013-03-26 2018-01-04 Celgene Corporation Solid forms comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
US20180230140A1 (en) * 2014-06-30 2018-08-16 Basf Se Multicomponent crystals of dasatinib with menthol or vanillin
WO2018129227A1 (en) * 2017-01-05 2018-07-12 Watson Laboratories Inc. Novel crystalline forms of selinexor and process for their preparation
CN107089946A (zh) * 2017-05-05 2017-08-25 浙江科技学院 一种诺氟沙星与香兰素共晶及其制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"医薬品原薬にcocrystalを適用するための評価および製造", ファルマシア, vol. 49, no. 12, JPN6021017243, 2013, pages 1201, ISSN: 0005316748 *
高田則幸: "Ｃｏｃｒｙｓｔａｌのスクリーニングと原薬物性改善への応用", PHARM TECH JAPAN, vol. 25, no. 12, JPN6013060384, 2009, pages 155 - 166, ISSN: 0005316749 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0005316750 *

Also Published As

Publication number Publication date
BR112021016762A2 (pt) 2021-10-19
US20210395232A1 (en) 2021-12-23
CA3130107A1 (en) 2020-09-24
KR20210141936A (ko) 2021-11-23
JP2025134935A (ja) 2025-09-17
CN113423468A (zh) 2021-09-21
EP3941588A1 (en) 2022-01-26
US12559478B2 (en) 2026-02-24
WO2020191140A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
JP6756617B2 (ja) Ｎ−｛４−［（６，７−ジメトキシキノリン−４−イル）オキシ］フェニル｝−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法
CN102510855B (zh) N-[3-氟-4-({6-(甲基氧基)-7-[(3-吗啉-4-基丙基)氧基]-喹啉-4-基}氧基)苯基]-n′-(4-氟苯基)环丙烷-1，1-二甲酰胺的晶形
JP7818666B2 (ja) ピリジノイルピペリジン５－ｈｔ１ｆアゴニストに関する組成物および方法
BR112013000980B1 (pt) Composições farmacêuticas moduladoras de c-met
JP2017505796A5 (https=)
CN102791719A (zh) 二胺衍生物的晶体及其制备方法
WO2014082354A1 (zh) 西达本胺的晶型及其制备方法与应用
CN111278808B (zh) 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式
JP2025134935A (ja) セリネクソールの共結晶形態
JP2023543055A (ja) テガビビントの結晶形態、調製方法、及びその使用
US12030886B2 (en) Form of ponatinib
JP2022540466A (ja) 非晶質ウムブラリシブモノトシレート
KR102858471B1 (ko) Lta4h 저해제의 결정질 형태
CN101111495B (zh) 晶体1h-咪唑并[4,5-b]吡啶-5-胺，7-[5-[(环己基甲基氨基)-甲基]-1h-吲哚-2-基]-2-甲基，硫酸盐(1:1)，三水合物及其药物用途
WO2023222122A1 (en) Solid forms of a compound for treating or preventing hyperuricemia or gout
CN1989129B (zh) 晶型转变了的(s)-(3-吡啶羧基酰胺,6-[4-[2-[[3-(9h-咔唑-4-基氧基)-2-羟丙基]氨基]-2-甲丙基]苯氧基]-半琥珀酸盐水合物
HK40079891A (en) Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists
HK40040786A (en) Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
CN109206407A (zh) 一种酪氨酸激酶抑制剂的二马来酸盐的晶型及其制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20211012

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230317

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240919

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20241107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250225

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250620

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260427